Angiopoietin-2: development of inhibitors for cancer therapy.
about
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapyDelineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease.Vaccines targeting the neovasculature of tumorsArray-based discovery of aptamer pairsQuantitative selection and parallel characterization of aptamers.Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer.Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathwayWhat role for angiogenesis in childhood acute lymphoblastic leukaemia?Elevated peripheral blood plasma concentrations of tie-2 and angiopoietin 2 in patients with neuroendocrine tumors.Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.Gastric tumour-derived ANGPT2 regulation by DARPP-32 promotes angiogenesisDual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft modelExpression of angiopoietin-TIE system components in angiosarcomaPredictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?MiR-145 functions as a tumor suppressor via regulating angiopoietin-2 in pancreatic cancer cells.Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.Angiogenesis in cancer: Anti-VEGF escape mechanismsSerum biomarker analysis in patients with recurrent spontaneous abortion.Oncogenic function of angiopoietin-2 in vitro and its modulation of tumor progression in colorectal carcinoma.Angiopoietin-2 inhibition using siRNA or the peptide antagonist L1-10 results in antitumor activity in human neuroblastoma.Knockdown of angiopoietin-2 suppresses metastasis in human pancreatic carcinoma by reduced matrix metalloproteinase-2.Pigment epithelium-derived factor (PEDF): a novel trophoblast-derived factor limiting feto-placental angiogenesis in late pregnancy.MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters.Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis.Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia.Angiopoietin-2 is expressed in oral Kaposi's sarcoma.The Role of Angiogenesis in Cancer Treatment.Growth Factor-Free Pre-vascularization of Cell Sheets for Tissue Engineering.The lymphangiogenic factor SOX 18: a key indicator to stage gastric tumor progression.Overexpression of Tie2 is associated with poor prognosis in patients with gastric cancer.Potential suppressive effects of theophylline on human rectal cancer SW480 cells in vitro by inhibiting YKL-40 expression.[The influence of inhibiting angiopoietin-2 on the biological characteristics of bronchogenic adenocarcinoma].Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
P2860
Q26784218-A88464A6-0F4E-4447-B26E-D6E95B6516FAQ31121875-4EEBD638-29B4-4B34-912A-5F1B11897E85Q33732486-7DF862E5-60FE-48DE-A5A2-B89D9FC39758Q33898877-264F366C-750F-48F5-8894-BF296C79098DQ34344165-9C0F2C3B-9423-4A30-BADE-92EE23604525Q34518898-E547F2ED-0A85-4012-BAA3-BDE7C2907489Q34704905-E90EBD9D-D8B4-4330-9576-58B149562679Q34879171-AC354CD1-8613-49D9-844D-B5B0FF9F567DQ35027580-84E2CB2C-6C7E-4A14-B39A-2367B36521F8Q35120530-27560D41-7BD9-4901-899C-C78A0780DAAFQ35144839-4FAD5472-F7B9-40AD-A8E5-FBD0D4FBDC96Q35310168-A78F2E01-9061-48C0-A3EA-28DBAD175242Q35550914-6F57B5B3-84EA-484C-844F-A4430864F0A6Q35795736-632846C8-4636-4797-B92A-A7CF2FA1C62EQ35881597-677C9655-8554-4525-810B-B90C1F5AACD5Q36069142-312D2A3C-1F17-48A7-B3F7-AADC7C003FD6Q36831553-DB4B60C8-BA27-4321-AE4F-458AB108F3BBQ36905630-2E7195BD-0027-4061-8296-B0F87EDC35E4Q36997066-11FE2877-9D79-47D5-82FC-75B95E1CA446Q37088265-2EEDEF14-D281-4DB8-8CB5-A0D9539F6FE5Q37209635-73A0E5FF-C269-45BC-86C2-B987C5A5103CQ38239003-6F0C8F3B-1CE2-4F2C-9464-AE66DA495C9CQ38389975-6CAD8495-B4EA-431F-A2DE-5670A8A58C9DQ38693339-57C55201-3921-4C19-9B5F-554560A845BCQ38697673-E439AE4E-B394-4B0B-99B2-28A0C68F4B19Q39317367-E1F51429-D5BD-49CB-A06B-E7687F56FAC0Q39372556-626E3440-8DAD-40FD-8CF0-7390BBB8A44FQ39698792-6B0CDD17-7EF9-4A5D-840F-75DC61935E6CQ40536884-3401A339-AF04-44A7-BABC-3359B85FC880Q42147633-3E6EE512-6ECF-4D6D-A2EE-46147AC4F7CCQ47207790-C89BEFD7-287B-412D-9425-3579C681F399Q48333282-E1D9C341-410B-4885-B090-C56EA707A5AAQ50932310-DF74C680-4B1E-4B1E-A157-3EFA8C1C1CE2Q51308312-3BA9F9C4-EF8E-485D-B1A9-1BB8A732A853Q54356965-E63FD9BA-DC90-4235-9191-E16126B59053Q54977592-66C83C91-748B-4F63-9431-78A6CD7EC9AFQ55210960-692B36B7-3572-48F9-8433-45A600F2436FQ55444655-9ECD98D7-D2EF-4C85-B2DD-36F4D2B6B778Q57067866-C00FC89A-332A-46C4-9CB0-3BD8206297FC
P2860
Angiopoietin-2: development of inhibitors for cancer therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Angiopoietin-2: development of inhibitors for cancer therapy.
@ast
Angiopoietin-2: development of inhibitors for cancer therapy.
@en
type
label
Angiopoietin-2: development of inhibitors for cancer therapy.
@ast
Angiopoietin-2: development of inhibitors for cancer therapy.
@en
prefLabel
Angiopoietin-2: development of inhibitors for cancer therapy.
@ast
Angiopoietin-2: development of inhibitors for cancer therapy.
@en
P2860
P1476
Angiopoietin-2: development of inhibitors for cancer therapy.
@en
P2093
P2860
P2888
P304
P356
10.1007/S11912-009-0017-3
P577
2009-03-01T00:00:00Z
P5875
P6179
1007927088